Cargando…
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
INTRODUCTION: There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some a...
Autores principales: | Golpe, Rafael, Pérez-de-Llano, Luis A., Dacal, David, Guerrero-Sande, Hector, Pombo-Vide, Beatriz, Ventura-Valcárcel, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832110/ https://www.ncbi.nlm.nih.gov/pubmed/33521300 http://dx.doi.org/10.1016/j.medcle.2020.06.028 |
Ejemplares similares
-
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020) -
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
por: Moon, Ju-Young
Publicado: (2013) -
Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020) -
Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023) -
Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
por: Cahova, Monika, et al.
Publicado: (2021)